Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583, a FLT3 Agonist Fc Fusion Protein, in Subjects With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1b Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583, a FLT3 Agonist Fc Fusion Protein, in Subjects With Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GS-3583 (Primary)
  • Indications Ovarian cancer; Pancreatic cancer; Rectal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 24 Mar 2023 Results of a population pharmacokinetic (popPK) model analysis using pooled data from two clinical studies: Phase 1 study in healthy volunteers (n=30) and a Phase 1b study in patients with solid tumors (n=13) presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 01 Dec 2022 Status changed from active, no longer recruiting to discontinued.
    • 16 Jun 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top